Biocon Biologics initiates clinical study for Itolizumab in Lupus Nephritis
Equalise is a phase-Ib open-label, proof-of-concept clinical study currently studying Lupus Nephritis patients in the Part B…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Research
University of Oxford study supports use of Vaxzevria as third-dose booster against Omicron
Neutralising anti-body levels against Omicron following a third-dose boost of Vaxzevria were broadly similar to levels achieved…
Valneva says Chikungunya vaccine phase-III trial has met primary endpoint
In August, after Valneva gave a positive update on the phase-III trial
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in…
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
South Africa begins trial of new oral drug against COVID-19
South Africa has been struggling with its plans to achieve herd immunity through vaccinations, with widespread vaccine hesitancy,…
Zydus receives Orphan Drug Designation from US FDA for malaria treatment
The Orphan Drug Designation provides up to seven years of marketing exclusivity in the US
Scientists develop molecule that blocks COVID-19 infection
The researchers at Aarhus University in Denmark noted that the molecule is cheaper and easier to manufacture than the antibodies…
Swarnajayanti fellow from CDRI probing mitochondrion of malaria parasite for hints into alternative…
Malaria biology is an interesting field not only from the perspective of biochemical or molecular investigations, but it also…
Zydus to begin phase-II (a) clinical trial of oral inflammasome inhibitor in patients with…
Cryopyrin-Associated Periodic Syndrome (CAPS) is a rare life-long auto-inflammatory condition, caused by NLRP3 activating…
Zydus announces EPICS-IIITM phase-II(b)/III adaptive pivotal clinical trial of Saroglitazar Mg in…
Positive results from the phase-II(a) clinical trial evaluating Saroglitazar Mg in patients with NASH were published in the…
US FDA grants EUA to AstraZeneca’s Evusheld in US for pre-exposure prophylaxis of COVID-19
Phase-III data showed at least six months of protection with one dose in high-risk participant population
CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
Actemra/RoActemra reduced the risk of death in patients with severe COVID-19, as evidenced by a review of four phase-III studies.…
Amgen announces positive top-line results from Otezla phase-III Discreet study in moderate-to-severe…
Otezla resulted in clinically and statistically significant improvements in measures of genital psoriasis at week 16 compared with…
Moderna COVID vaccine highly effective five months after second dose: Study
Funded by Moderna, the study included 352,878 recipients of two doses of the vaccine matched to 352,878 unvaccinated individuals…
Antibody drug works against COVID-19 Omicron variant: GSK
In a statement, the British drugmaker said that lab tests and a study on hamsters have demonstrated the Sotrovimab antibody…
Emmes completes third ACTT clinical trial for COVID
The ACTT-III trial assessed the efficacy and safety of interferon beta-1a plus Remdesivir compared to Remdesivir alone in…
ITC starts clinical trials of nasal spray for COVID-19 prevention
Developed by scientists at ITC Life Sciences and Technology Centre (LSTC), Bengaluru, the company plans to market the nasal spray…
US FDA approves Takeda’s Livtencity to treat people with post-transplant Cytomegalovirus infection
In the phase-III Solstice study, more than twice the proportion of adult transplant recipients with refractory or resistant (R/R)…
Covaxin shows 50 per cent effectiveness against symptomatic COVID in real-world assessment: Lancet…
The latest study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi, from 15th April…
Gilead submits Biologics Licence Application to USFDA for Bulevirtide
If approved, Bulevirtide will be the first treatment option for adult patients in the US with chronic Hepatitis Delta Virus…